NDA 203231 · Inforlife
Zoledronic Acid
Zoledronic Acid · Intravenous
Last checked: Nov 19, 2026Latest source record: Apr 5, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Aug 2, 2013
Approved uses
1
Original approval plus efficacy supplements
Registered trials
363
118 Phase 3, 24 recruiting
FAERS reports
27,217
25,233 serious, 3,128 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 11, 2025.
Zoledronic Acid Injection is a bisphosphonate indicated for the treatment of: Hypercalcemia of malignancy. ( 1.1 ) Patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy. ( 1.2 ) Limitations of Use : The safety and efficacy of Zoledronic Acid Injection has not been established for use in hyperparathyroidism or non-tumor-related hypercalcemia. 1.1 Hypercalcemia of Malignancy Zoledronic Acid Injection is indicated for the treatment of hypercalcemia of malignancy defined as an albumin-corrected calcium (cCa) of greater than or equal to 12 mg/dL [3 mmol/L] using the formula: cCa in mg/dL = Ca in mg/dL + 0.8 (4 g/dL – patient albumin [1g/dL]). 1.2 Multiple Myeloma and Bone Metastases of Solid Tumors Zoledronic Acid Injection is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy. Limitations of Use The safety and efficacy of Zoledronic Acid Injection in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions have not been established.
Mechanism: The principal pharmacologic action of zoledronic acid is inhibition of bone resorption. Although the antiresorptive mechanism is not completely understood, several factors are thought to contribute to this action. In vitro , zoledronic acid inhibits osteoclastic activity and induces osteoclast apoptosis. Zoledronic acid also blocks the osteoclastic resorption of mineralized bone and cartilage through its binding to bone. Zoledronic acid inhibits the increased osteoclastic activity and skeletal calcium release induced by various stimulatory factors released by tumors.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ZOLEDRONIC ACID · ZOLEDRONIC ACID EQ 4MG BASE/100ML · INJECTABLE, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Zoledronic Acid" as an intervention, any sponsor and status, largest first.
- Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug EfficacyPivotal-lookingActive, not recruiting
Medical Research CouncilGovernment (non-federal)
NCT00268476 · 11,992 participants · Start Jul 8, 2005 · Primary completion Mar 2026
Drug: Celecoxib; Docetaxel and 7 more · For: Prostate Cancer
Sites: Lausanne, Switzerland; Winterthur, Switzerland; Chur, Switzerland · 120 sites in all
- HORIZON-PFT: Pivotal Fracture TrialPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00049829 · 7,700 participants · Start Jan 2002 · Primary completion Jun 2006
Drug: Zoledronic Acid · For: Osteoporosis
Sites: Birmingham, Alabama; Paradise Valley, Arizona; Tucson, Arizona · 60 sites in all
- S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.Pivotal-lookingCompleted
SWOG Cancer Research NetworkResearch network
NCT00127205 · 6,097 participants · Start Jul 2005 · Primary completion Dec 2017
Drug: clodronate disodium; ibandronate sodium and 1 more · For: Breast Cancer
- Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-TrialPivotal-lookingCompleted
Ludwig-Maximilians - University of MunichAcademic, hospital or other
NCT02181101 · 3,754 participants · Start Sep 2005 · Primary completion Sep 2013
Drug: FEC-DocGemzar adjuvant chemotherapy; FEC-Doc adjuvant chemotherapy and 2 more · For: Breast Neoplasms
Sites: Munich, Germany
- Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor TherapyPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00556374 · 3,420 participants · Start Dec 18, 2006 · Primary completion Oct 7, 2014
Drug: Placebo; Denosumab and 2 more · For: Breast Cancer
Sites: Baden, Austria; Braunau am Inn, Austria; Dornbirn, Austria · 46 sites in all
- Trial of Parkinson's And Zoledronic AcidPivotal-lookingCompleted
California Pacific Medical Center Research InstituteAcademic, hospital or other
NCT03924414 · 2,721 participants · Start Nov 15, 2019 · Primary completion Feb 28, 2026
Drug: Zoledronic Acid 5Mg/Bag 100Ml Inj · For: Parkinson Disease; Osteoporosis; Parkinsonism and 6 more
Sites: Scottsdale, Arizona; Fayetteville, Arkansas; Little Rock, Arkansas · 77 sites in all
- The Effect of Zoledronate on the Prevention of Pneumonia in Hip Fracture PatientsPivotal-lookingStatus unknown
The University of Hong KongAcademic, hospital or other
NCT05743179 · 2,692 participants (planned) · Start Dec 5, 2022 · Primary completion May 2025
Drug: Zoledronate · For: Hip Fractures; Pneumonia
Sites: Hong Kong, Hong Kong; Kwun Tong, Hong Kong; Sham Shui Po, Hong Kong · 5 sites in all
- Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)Pivotal-lookingCompleted
NovartisNovartis (NVS)
NCT00145327 · 2,456 participants · Start May 2005 · Primary completion Nov 2009
Drug: Zoledronic Acid; Placebo · For: Osteoporosis
Sites: Tucson, Arizona; Little Rock, Arkansas; Beverly Hills, California · 31 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- osteonecrosis of jaw2,541
- fatigue1,931
- nausea1,778
- diarrhoea1,776
- pyrexia1,668
- off label use1,602
- pain1,456
- arthralgia1,433
- neutropenia1,410
- vomiting1,409
- asthenia1,338
- malignant neoplasm progression1,202
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 40 |
| 2005 | 92 |
| 2006 | 108 |
| 2007 | 227 |
| 2008 | 419 |
| 2009 | 563 |
| 2010 | 324 |
| 2011 | 874 |
| 2012 | 362 |
| 2013 | 385 |
| 2014 | 431 |
| 2015 | 700 |
| 2016 | 931 |
| 2017 | 1,135 |
| 2018 | 1,718 |
| 2019 | 2,096 |
| 2020 | 2,222 |
| 2021 | 2,202 |
| 2022 | 2,342 |
| 2023 | 2,535 |
| 2024 | 2,713 |
| 2025 | 2,908 |
| 2026 | 1,889 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zoledronic Acid (Zoledronic Ac/Mannitol/0.9nacl)
2024 spending
$86K
Beneficiaries
204
583 claims
Per beneficiary
$422
$1.48 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $43,086 |
| 2021 | $58,148 |
| 2022 | $51,125 |
| 2023 | $73,051 |
| 2024 | $86,081 |
Part D: Zoledronic Acid (Zoledronic Acid)
2024 spending
$438K
Beneficiaries
1,238
3,990 claims
Per beneficiary
$354
$21.58 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $569,738 |
| 2021 | $549,792 |
| 2022 | $663,024 |
| 2023 | $777,184 |
| 2024 | $438,227 |
Part D: Zoledronic Acid (Zoledronic Acid/Mannitol-Water)
2024 spending
$1.6M
Beneficiaries
10,061
10,184 claims
Per beneficiary
$156
$1.54 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,209,131 |
| 2021 | $1,293,328 |
| 2022 | $1,681,536 |
| 2023 | $1,821,924 |
| 2024 | $1,569,038 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Safety and Efficacy of Denosumab in Children With Osteogenesis Imperfecta-the First Prospective Comparative Study.
Liu J, Lin X, Sun L, et al. · J Clin Endocrinol Metab 2024 · Randomized Controlled Trial, Comparative Study
- Zoledronic acid and clinical fractures and mortality after hip fracture.
Lyles KW, Colón-Emeric CS, Magaziner JS, et al. · N Engl J Med 2007 · Multicenter Study, Randomized Controlled Trial
- Denosumab vs. bisphosphonates in primary osteoporosis: a meta-analysis of comparative safety in randomized controlled trials.
Kobayashi T, Morimoto T, Ito K, et al. · Osteoporos Int 2024 · Meta-Analysis, Comparative Study
- Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
Stopeck AT, Lipton A, Body JJ, et al. · J Clin Oncol 2010 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Zoledronic acid and fracture risk: a meta-analysis of 12 randomized controlled trials.
He B, Zhao JQ, Zhang MZ, et al. · Eur Rev Med Pharmacol Sci 2021 · Meta-Analysis, Systematic Review
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
Fizazi K, Carducci M, Smith M, et al. · Lancet 2011 · Clinical Trial, Phase III, Comparative Study
Sponsor: Inforlife
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.